Published in:
Open Access
01-12-2011 | Short report
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
Authors:
Stephanie E Combs, Stefan Rieken, Wolfgang Wick, Amir Abdollahi, Andreas von Deimling, Jürgen Debus, Christian Hartmann
Published in:
Radiation Oncology
|
Issue 1/2011
Login to get access
Abstract
A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase (IDH)1-mutational status. Unexpectedly, overall survival or progression-free survival were not longer in the group with methylated MGMT-promoter as compared to patients without that methylation. IDH-1 mutations were significantly associated with increased overall survival.